Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Hope

Showing results (141-150 of 143) with videos related to

Pageof 15
Sort By:
You have reached the last page of results.This site can display upto 143 results.
Multiple Sclerosis and Related Disorders|April 15, 2025
A cross-sectional multicentre study of multishell diffusion MRI in multiple sclerosisEinar A Høgestøl, Daniel A Rinker, Ivan Maximov, et al.
Gynecologic Oncology|April 9, 2024
Disease progression, survival, and molecular disparities in Black and White patients with endometrioid endometrial carcinoma in real-world registries and GOG/NRG oncology randomized phase III clinical trialsZachary A Kopelman, Chunqiao Tian, Jordyn Tumas, et al.
Journal of Medicinal Chemistry|May 13, 2017
Discovery of Clinical Candidate 1-{[(2S,3S,4S)-3-Ethyl-4-fluoro-5-oxopyrrolidin-2-yl]methoxy}-7-methoxyisoquinoline-6-carboxamide (PF-06650833), a Potent, Selective Inhibitor of Interleukin-1 Receptor Associated Kinase 4 (IRAK4), by Fragment-Based Drug DesignKatherine L Lee, Catherine M Ambler, David R Anderson, et al.
Pageof 15

Showing results (141-150 of 143) with videos related to

Sort By:
Pageof 15
You have reached the last page of results.This site can display upto 143 results.
Multiple Sclerosis and Related Disorders|April 15, 2025
A cross-sectional multicentre study of multishell diffusion MRI in multiple sclerosisEinar A Høgestøl, Daniel A Rinker, Ivan Maximov, et al.
Gynecologic Oncology|April 9, 2024
Disease progression, survival, and molecular disparities in Black and White patients with endometrioid endometrial carcinoma in real-world registries and GOG/NRG oncology randomized phase III clinical trialsZachary A Kopelman, Chunqiao Tian, Jordyn Tumas, et al.
Journal of Medicinal Chemistry|May 13, 2017
Discovery of Clinical Candidate 1-{[(2S,3S,4S)-3-Ethyl-4-fluoro-5-oxopyrrolidin-2-yl]methoxy}-7-methoxyisoquinoline-6-carboxamide (PF-06650833), a Potent, Selective Inhibitor of Interleukin-1 Receptor Associated Kinase 4 (IRAK4), by Fragment-Based Drug DesignKatherine L Lee, Catherine M Ambler, David R Anderson, et al.
Pageof 15